Clinical Trials Browser

Completed × Bortezomib × Myeloid × Clear all

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02312102 2026-01-16

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Phase 1 Completed

22 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02211755 2025-11-28

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Phase 1 Completed

28 enrolled

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes, Neoplasms

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Phase 1 Completed

15 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Phase 2 Completed

279 enrolled 28 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00789256 2018-10-24

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Phase NA Completed

26 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01891968 2018-04-23

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Phase 2 Completed

15 enrolled 7 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT00624936 2017-08-22

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 1 Completed

23 enrolled

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT01323920 2017-05-30

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Phase 2 Completed

35 enrolled 9 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes

NCT01174888 2016-07-06

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Completed

34 enrolled

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01075425 2016-04-15

Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

41 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00437086 2014-10-17

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Phase EARLY_PHASE1 Completed

30 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT00006098 2013-06-18

PS-341 in Treating Patients With Hematologic Cancer

Phase 1 Completed

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

Clinical Trials

Natural Killer Cells and Bortezomib to Treat Cancer

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

PS-341 in Treating Patients With Hematologic Cancer